Literature DB >> 23006324

Looking in the miR-ror: TGF-β-mediated activation of NF-κB in glioma.

Christine E Eyler1, Jeremy N Rich.   

Abstract

The explosive growth in our understanding of the molecular underpinnings of glioblastomas has served as an instructive paradigm for other cancers. However, the exact nature by which many of the pathogenic drivers connect is less well known, and elucidation of relationships between critical genetic and signaling alterations may inform the development of therapeutic approaches to the disease. In this issue, Song et al. identify miR-182 induction as a mechanism by which TGF-β stimulation aberrantly activates NF-κB signaling in glioblastoma cells, clarifying a critical point of cross-talk between molecular signaling pathways. Their findings provide a greater understanding of the complex interplay between signaling pathways in cancer that may ultimately prove useful in the development of synergistic targeting approaches.

Entities:  

Year:  2012        PMID: 23006324      PMCID: PMC3461933          DOI: 10.1172/JCI66058

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  18 in total

1.  The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF-kappa B. Identification of a novel receptor-tyrosine kinase signalosome.

Authors:  A A Habib; S Chatterjee; S K Park; R R Ratan; S Lefebvre; T Vartanian
Journal:  J Biol Chem       Date:  2000-12-14       Impact factor: 5.157

2.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.

Authors:  Jeongwu Lee; Svetlana Kotliarova; Yuri Kotliarov; Aiguo Li; Qin Su; Nicholas M Donin; Sandra Pastorino; Benjamin W Purow; Neil Christopher; Wei Zhang; John K Park; Howard A Fine
Journal:  Cancer Cell       Date:  2006-05       Impact factor: 31.743

Review 3.  Escaping from the TGFbeta anti-proliferative control.

Authors:  Joan Seoane
Journal:  Carcinogenesis       Date:  2006-05-12       Impact factor: 4.944

Review 4.  The role of transforming growth factor-beta in primary brain tumors.

Authors:  Jeremy N Rich
Journal:  Front Biosci       Date:  2003-01-01

5.  High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.

Authors:  Alejandra Bruna; Rachel S Darken; Federico Rojo; Alberto Ocaña; Silvia Peñuelas; Alexandra Arias; Raquel Paris; Avelina Tortosa; Jaume Mora; Jose Baselga; Joan Seoane
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

6.  Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.

Authors:  Jayne M Stommel; Alec C Kimmelman; Haoqiang Ying; Roustem Nabioullin; Aditya H Ponugoti; Ruprecht Wiedemeyer; Alexander H Stegh; James E Bradner; Keith L Ligon; Cameron Brennan; Lynda Chin; Ronald A DePinho
Journal:  Science       Date:  2007-09-13       Impact factor: 47.728

Review 7.  Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments.

Authors:  Alba A Brandes; Enrico Franceschi; Alicia Tosoni; Monika E Hegi; Roger Stupp
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

8.  Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways.

Authors:  Jae-Il Park; Min-Goo Lee; Kyucheol Cho; Bum-Joon Park; Kwon-Seok Chae; Do-Sun Byun; Byung-Kyu Ryu; Yong-Keun Park; Sung-Gil Chi
Journal:  Oncogene       Date:  2003-07-10       Impact factor: 9.867

9.  Distinct domains in the SHP-2 phosphatase differentially regulate epidermal growth factor receptor/NF-kappaB activation through Gab1 in glioblastoma cells.

Authors:  Gurpreet S Kapoor; Yi Zhan; Gibbes R Johnson; Donald M O'Rourke
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

10.  Altered TAB1:I kappaB kinase interaction promotes transforming growth factor beta-mediated nuclear factor-kappaB activation during breast cancer progression.

Authors:  Jason R Neil; William P Schiemann
Journal:  Cancer Res       Date:  2008-03-01       Impact factor: 12.701

View more
  5 in total

1.  Cytoplasmic TRADD confers a worse prognosis in glioblastoma.

Authors:  Sharmistha Chakraborty; Li Li; Hao Tang; Yang Xie; Vineshkumar Thidil Puliyappadamba; Jack Raisanen; Sandeep Burma; David A Boothman; Brent Cochran; Julian Wu; Amyn A Habib
Journal:  Neoplasia       Date:  2013-08       Impact factor: 5.715

2.  Inflammation and Gliomagenesis: Bi-Directional Communication at Early and Late Stages of Tumor Progression.

Authors:  Rui Pedro Galvão; Hui Zong
Journal:  Curr Pathobiol Rep       Date:  2013-03-01

Review 3.  Aging, Melatonin, and the Pro- and Anti-Inflammatory Networks.

Authors:  Rüdiger Hardeland
Journal:  Int J Mol Sci       Date:  2019-03-11       Impact factor: 5.923

Review 4.  A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.

Authors:  Richard E Kast; John A Boockvar; Ansgar Brüning; Francesco Cappello; Wen-Wei Chang; Boris Cvek; Q Ping Dou; Alfonso Duenas-Gonzalez; Thomas Efferth; Daniele Focosi; Seyed H Ghaffari; Georg Karpel-Massler; Kirsi Ketola; Alireza Khoshnevisan; Daniel Keizman; Nicolas Magné; Christine Marosi; Kerrie McDonald; Miguel Muñoz; Ameya Paranjpe; Mohammad H Pourgholami; Iacopo Sardi; Avishay Sella; Kalkunte S Srivenugopal; Marco Tuccori; Weiguang Wang; Christian R Wirtz; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2013-04

5.  Nano-delivery of fraxinellone remodels tumor microenvironment and facilitates therapeutic vaccination in desmoplastic melanoma.

Authors:  Lin Hou; Qi Liu; Limei Shen; Yun Liu; Xueqiong Zhang; Fengqian Chen; Leaf Huang
Journal:  Theranostics       Date:  2018-06-13       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.